Please use this identifier to cite or link to this item:
Title: Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Authors: Longo-Muñoz, F
Argiles, G
Tabernero, J
Cervantes, A
Gravalos, C
Pericay, C
Gil-Calle, S
Mizuguchi, H
Carrato-Mena, A
Limón, M L
Garcia-Carbonero, R
Keywords: Fluoropyrimidine;Metastatic colorectal cancer;Spain;TAS-102;Tipiracil hydrochloride;Trifluridine
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Antiviral Agents
Colorectal Neoplasms
Double-Blind Method
Drug Combinations
Drug Therapy, Combination
Follow-Up Studies
Middle Aged
Neoplasm Staging
Palliative Care
Survival Rate
Issue Date: 21-Jul-2016
Abstract: TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P  Primary and key secondary endpoints were evaluated in a post hoc analysis of the RECOURSE Spanish subgroup, using univariate and multivariate analyses. Safety and tolerability were reported with descriptive statistics. The RECOURSE Spanish subgroup included 112 patients (mean age 61 years, 62 % male). Median OS was 6.8 months in the TAS-102 group (n = 80) versus 4.6 months in the placebo group (n = 32) [HR = 0.47; 95 % confidence interval (CI): 0.28-0.78; P = 0.0032). Median PFS was 2.0 months in the TAS-102 group and 1.7 months in the placebo group (HR = 0.47; 95 % CI: 0.30-0.74; P = 0.001). Eighty (100 %) TAS-102 versus 31 (96.9 %) placebo patients had adverse events (AEs). The most common drug-related ≥Grade 3 AE was neutropenia (40 % TAS-102 versus 0 % placebo). There was 1 (1.3 %) case of febrile neutropenia in the TAS-102 group versus none in the placebo group. In the RECOURSE Spanish subgroup, TAS-102 was associated with significantly improved OS and PFS versus placebo, consistent with the overall RECOURSE population. No new safety signals were identified. CLINICALTRIALS. NCT01607957.
metadata.dc.identifier.doi: 10.1007/s12094-016-1528-7
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5239803.pdf1,02 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons